RecruitingPHASE1, PHASE2INTERVENTIONAL

A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that makes it difficult to breathe. Researchers are developing a new medicine, called RO7830698, to see if it could help. This early-stage clinical trial aims to test how safe the medicine is, what side effects it might cause, and how the body handles it. The trial is split into two groups. The first group looks at healthy volunteers, while the second group looks at adults diagnosed with COPD who use regular maintenance inhalers. Some participants will receive the real study drug, while others will receive a dummy medicine called a placebo. By comparing the two, doctors can see the genuine effects of the treatment. Taking part involves health checks and close monitoring by medical experts, helping researchers learn whether this medicine could become a future treatment option for lung disease.

At a glance

Status

Recruiting

Phase

PHASE1, PHASE2

Sponsor

Hoffmann-La Roche

Enrolment target

104

Start

20 Oct 2026

Estimated completion

20 Jun 2029

Chronic Obstructive Pulmonary Disease (COPD)Healthy Participants

What is this study about?

Chronic obstructive pulmonary disease, commonly known as COPD, is a long-term condition that causes inflammation and narrowing in the airways, making breathing difficult. Everyday tasks can leave people feeling short of breath, tired, and prone to chest infections. While existing inhalers help manage these symptoms, there is still a vital need for new treatments that can calm inflammation in the lungs and improve daily life.

This clinical trial is looking at an experimental drug named RO7830698. Because the medicine is in its early testing stages, doctors first need to understand its safety profile. They want to see how the human body processes the drug, how long it stays in the system, and whether it triggers any unexpected reactions or side effects.

To get a clear and complete picture, researchers are testing the drug in two distinct stages. First, they are studying healthy volunteers to see how the drug behaves in a body with no lung problems. Next, they are testing it in people who have lived with COPD for at least six months. Some people will be given a placebo, which looks identical to the real drug but contains no active medicine. This allows doctors to prove that any changes observed are truly caused by the study drug.

Studies like this are an essential step in finding new healthcare options. Even though this trial will not immediately cure COPD, the answers it provides could pave the way for more effective, tailored medicines in the future.

Key takeaways

Testing a new medicine called RO7830698 for safety, side effects, and how it moves through the body.
Open to both healthy volunteers and people with diagnosed COPD aged 18 to 80.
Compares the study drug with an inactive dummy treatment (placebo).
Requires regular clinic visits for blood tests, health checks, and symptom monitoring.
Participation is entirely voluntary, and you can leave at any time without impacting your regular NHS care.

Who may be eligible?

This trial is open to adults aged between 18 and 80. To take part, your body mass index (BMI) must be within a healthy-to-overweight range (between 18 and 32), and you must be willing to follow specific rules about using reliable contraception during the study.

The trial has two different groups. For the first group, researchers are seeking healthy volunteers who have no long-term illnesses. For the second group, researchers are looking for people who have been diagnosed with COPD for more than six months. People in this second group must be regular users of maintenance inhalers and be current or former smokers with a history of regular tobacco use over several years.

You will not be able to take part if you are pregnant, breastfeeding, or planning a pregnancy. The trial is also not suitable for people with significant heart or liver disease, a history of frequent severe infections, autoimmune conditions, or active infections such as hepatitis, tuberculosis, or HIV. People taking certain other medicines that suppress the immune system are also excluded to protect their safety.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am aged between 18 and 80 years old.
My BMI is between 18 and 32.
I am either in good health with no long-term illnesses, OR I have had COPD for at least 6 months.
If I have COPD, I use daily maintenance inhalers and have a history of smoking.
I am not pregnant, breastfeeding, or living with serious liver, heart, or immune conditions.

Answer every question to see your result.

What does participation involve?

If you decide to join, you will first attend a screening visit to check your general health through blood tests, heart checks (ECGs), and lung measurements. During the trial, you will receive either the study medicine (RO7830698) or a dummy treatment (placebo). Depending on your group, you may receive a single dose or multiple doses over time. You will need to visit the clinic regularly so doctors can check your vital signs, collect blood samples to see how your body breaks down the drug, and ask about any symptoms or side effects. The study team will explain the exact number of visits, clinic stays, and follow-up checks before you agree to take part.

Potential risks and benefits

You may not get any direct health benefit from taking part in this early-stage trial, though your health will be watched very closely by medical specialists. The main benefit is helping doctors discover if this new treatment could help future patients with lung disease. As with all new medicines, there is a risk of side effects, some of which may be unexpected, as well as minor discomfort from blood tests. Taking part is completely voluntary. You are free to leave the study at any time without giving a reason, and doing so will not affect your normal NHS medical care.

Locations (1)

Medicines Evaluation Unit
Verified postcode
Wythenshawe, United Kingdom· Recruiting

Common questions

What is a placebo?

A placebo is a dummy treatment that looks just like the real medicine but contains no active ingredients. It helps doctors see if changes in health are genuinely caused by the study drug.

Will I have to stop using my regular COPD inhalers?

No, participants with COPD are expected to continue their regular daily maintenance inhalers, but the trial doctor will review all your current medicines to ensure they are safe to use together.

Do I have to pay to take part?

No, clinical trials do not cost you anything. The study medicine, tests, and care are provided free of charge, and travel expenses are often reimbursed.

Can I leave the study if I change my mind?

Yes. You can withdraw from the study at any point. Your decision will not change how your regular doctors look after you.

Why are healthy people included in a COPD trial?

Testing a drug in healthy people first helps researchers learn how it behaves naturally in the human body before checking how it works in people with lung conditions.

How to find out more

Reference Study ID Number: WP46321 https://forpatients.roche.com/ No attachments to email below.

global-roche-genentech-trials@gene.com 888-662-6728 (U.S. and Canada) Official trial record

Always speak to your GP or specialist before deciding to take part in a study.